‘A True Breakthrough’: Experts Say Personalized mRNA Vaccine Could Help Stop Melanoma From Returning and Become a New Standard of Care

“Cancer vaccines have always seemed to hold great promise, but the field has met several challenges, including drugs that looked great in earlier trials but failed this step. Success at this level using this type of patient-specific mRNA vaccine represents a true breakthrough,” Dr. Jeff Ishizuka, a medical oncologist at Yale School of Medicine, tells SurvivorNet.

A phase 3 clinical trial, INTerpath-001, evaluated personalized vaccine intismeran autogene (also known as V940 or mRNA-4157). The vaccine, developed by Moderna and Merck, was given after surgery in combination with immunotherapy drug pembrolizumab (brand name: Keytruda) in patients who were considered high-risk of having their melanoma return.

The trial enrolled patients with completely resected (fully removed through surgery) stage IIB–IV melanoma and tested the combination as adjuvant therapy, an additional treatment given after surgery in an attempt to keep cancer under control for longer.

The study met its primary endpoint of recurrence‑free survival (RFS) and a key secondary endpoint of distant metastasis‑free survival (DMFS), which means how long a patient lives without the cancer spreading.

How Could a Melanoma Vaccine Change the Standard Approach to Care?

Dr. Ahmad Tarhini, a medical oncologist at Moffitt Cancer Center, says, “If this immunotherapy regimen is granted FDA approval, it is expected to become a frontline treatment option. Therefore, melanoma specialists will be discussing intismeran plus Keytruda with all eligible patients.”

Moderna notes this is the first positive phase 3 result for an individualized neoantigen therapy and an mRNA‑based cancer treatment. It’s also the first phase 3 trial to show a meaningful improvement over Keytruda alone in the adjuvant melanoma setting. A neoantigen therapy is a type of personalized cancer treatment designed to train the immune system to recognize and attack a patient’s specific tumor.

It’s important to note that the full data have not yet been released. Moderna and Merck say they plan to present detailed trial results at an upcoming international medical meeting.

Dr. Douglas Johnson, clinical director of melanoma at Vanderbilt-Ingram Cancer Center, tells SurvivorNet this regimen could become a new standard of care for patients with high-risk stage II to IV melanoma, “a large population that needs more effective treatment options.”

“It is also possible, depending on the magnitude of benefit, that it could reignite the debate about whether adjuvant vs neoadjuvant therapy is more effective in certain patients with stage III melanoma,” Dr. Johnson adds.

For practicing physicians, Dr. Raman Madan, chief of dermatology at Northwell Health, believes this regimen “could make tumor sequencing and obtaining adequate tissue increasingly important early in the treatment process because the vaccine is individualized to each patient’s tumor. Specialists will also need to weigh the added benefit against manufacturing time, toxicity, cost, and an individual patient’s recurrence risk.”

WATCH: Routine Screening Helps Monitor for Melanoma Recurrence

As Merck Research Laboratories President Dr. Dean Y. Li explains, the goal of adjuvant therapy after surgery is to increase the chance of cure for more patients.

The latest, phase 3 findings build on promising results from a smaller, phase 2b study, KEYNOTE‑942/mRNA‑4157‑P201, which included five‑year follow‑up data and was presented at the 2026 ASCO Annual Meeting.

In that study, the vaccine + immunotherapy combination:

• Reduced the risk of recurrence or death by 49%
• Reduced the risk of distant metastasis or death by 59% compared with Keytruda alone

“Given that this phase 3 study, INTerpath-001, appears to confirm prior promising data from a smaller study (KEYNOTE-942), there is a high chance that intismeran plus Keytruda will change the adjuvant melanoma treatment standard of care,” Dr. Tarhini tells SurvivorNet.

How Do mRNA Vaccines Work?

The mRNA vaccines used in this study represent a personalized approach, Dr. Ishizuka explains.

“A sample of the patient’s tumor has genetic sequencing performed to identify specific targets for the immune system. Then an individualized vaccine is made to stimulate an immune attack on those targets and delivered in a lipid particle — like a soap bubble — so that it can enter cells and be expressed when injected. Together, these components steer the immune system to attack the tumor targets,” Dr. Ishizuka says.

Dr. Ishizuka believes the latest results on the mRNA vaccine serve as a “critical proof of concept: for cancer vaccines, for personalized vaccines, and for mRNA as an approach.”

“These results, if borne out by the data when it comes out, should drive investment in this approach in other cancers and potentially in off-the-shelf mRNA vaccines that don’t need to be personalized or in other technologies that push mRNA reprogramming of immunity even further,” Dr. Ishizuka tells SurvivorNet.

Building on Immunotherapy’s Benefit

Immunotherapy dramatically reshaped melanoma treatment, changing the disease from a cancer with few effective options to one where long‑lasting responses became possible.

For early‑stage melanoma, surgery alone can be curative. For higher‑risk cases, doctors often recommend adjuvant therapy to reduce the chance of recurrence.

“The opportunity to improve on already historically meaningful benefits from anti-PD-1 therapy is the end product of some very advanced and thoughtful science,” Dr. Benjamin Schmidt, surgical oncologist and the clinical director for cutaneous malignancies at VCU Massey Comprehensive Cancer Center, tells SurvivorNet.

“I am eagerly awaiting the presentation of the data and a response from the FDA,” he adds.

Currently, FDA‑approved adjuvant options for melanoma include:

• Pembrolizumab (Keytruda): A PD‑1 inhibitor that helps the immune system recognize and attack cancer cells
• Nivolumab (Opdivo): Another PD‑1 inhibitor with similar activity
• Dabrafenib (Tafinlar) + trametinib (Mekinist): Targeted therapy for tumors with BRAF V600E/K mutations, found in ~50% of melanomas
• Ipilimumab (Yervoy): A CTLA‑4 inhibitor that activates T cells

WATCH: Immunotherapy Helps Your Body Help Itself

Checkpoint inhibitors, such as Keytruda, work by blocking proteins cancer cells use to hide from the immune system, allowing immune cells to recognize and attack tumors with less damage to healthy tissue.

Possible immunotherapy side effects include:

• Fatigue
• Rash
• Cough
• Nausea
• Diarrhea
• Constipation
• Low thyroid levels
• Abdominal pain

A study in JAMA Oncology found that long‑lasting immune‑related side effects may be more common than previously recognized, affecting organs such as the thyroid, salivary glands, and joints.

Dr. Johnson notes that despite these risks, anti‑PD‑1 drugs remain transformative.

WATCH: Tell Your Doctor About Immunotherapy Side Effects

Questions To Ask Your Doctor

• Is the intismeran autogene vaccine a potential option for me?
• What are the risks/benefits of the vaccine/immunotherapy combination?
• Is my melanoma considered high-risk?
• Are there any clinical trials I should consider enrolling in?
• Is adjuvant therapy recommended in my case? Why?

Learn more about SurvivorNet's rigorous medical review process.

---